Effects of the SGLT2 Inhibitor Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes: A Randomized, Double-Blind Crossover Trial-Reference-Cited by-同舟云学术

Effects of the SGLT2 Inhibitor Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes: A Randomized, Double-Blind Crossover Trial

Published:2021-04-15 Issue:6 Volume:44 Page:1334-1343
ISSN:0149-5992
Container-title:Diabetes Care
language:en
Short-container-title:Dia Care

Author:

Op den Kamp Yvo J.M.,de Ligt Marlies,Dautzenberg Bas,Kornips Esther,Esterline Russell,Hesselink Matthijs K.C.^ORCID,Hoeks Joris^ORCID,Schrauwen-Hinderling Vera B.,Havekes Bas,Oscarsson Jan,Phielix Esther^ORCID,Schrauwen Patrick^ORCID

Funder

AstraZeneca

Publisher

American Diabetes Association

Subject

Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference33 articles.

1. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin

2. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

3. Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?;Coleman;Diabetes Obes Metab,2020

4. Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dapagliflozin in heart failure and type 2 diabetes: Efficacy, cardiac and renal effects, safety;World Journal of Diabetes;2024-07-15

2. Treatment of chronic kidney disease in older populations;Nature Reviews Nephrology;2024-07-08

3. SGLT2 Inhibitor Dapagliflozin Increases Skeletal Muscle and Brain Fatty Acid Uptake in Individuals With Type 2 Diabetes: A Randomized Double-Blind Placebo-Controlled Positron Emission Tomography Study;Diabetes Care;2024-06-28

4. Glucagon-Like Peptide-1 Receptor Agonists and Sodium Glucose Cotransporter-2 Inhibitors and Cardiorespiratory Fitness Interaction;Military Medicine;2024-06-13

5. Empagliflozin mitigates metabolic dysfunction‐associated steatotic liver disease by reducing de novo lipogenesis in a mouse model of lipoatrophic diabetes;Diabetes, Obesity and Metabolism;2024-05-03